FENNEC PHARMACEUTICALS INC. 4,800,000 Common Shares, no par value Underwriting AgreementUnderwriting Agreement • May 4th, 2020 • Fennec Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMay 4th, 2020 Company Industry JurisdictionFennec Pharmaceuticals Inc., a British Columbia corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 4,800,000 of its common shares, no par value per share (the “Shares”). The 4,800,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 720,000 Shares pursuant to such option are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herein shall mean Cantor, as Underwr